Reconnoitre ameloblastic carcinoma: A prognostic update

Saluja, Tajindra Singh; Hosalkar, Rashmi Maruti

doi:10.1016/j.oraloncology.2017.12.018

Cited by 18 publications

(14 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Some authors have also illuminated that it is not essential to categorize AC into primary and secondary. 11,[18][19][20] But Wu et al 21 found that secondary AC shows a more unfavorable prognosis compared with primary AC. The clinical manifestations of AC are complex and diverse.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ameloblastic carcinoma: Clinicopathological analysis of 18 cases and a systematic review

Deng

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Objectives Exploring the clinicopathological features of ameloblastic carcinoma (AC) and reviewing the literature to improve the diagnosis and treatment of the disease. Materials and Methods Clinical data and pathological features of 18 cases of AC were retrospectively analyzed. A systematic review was carried out by searching PubMed and Medline databases using the MeSH terms “ameloblastic” and “carcinoma.” Results In the systematic analysis, 125 cases of AC from 81 eligible original studies and 18 cases of AC from this research were included. The male‐to‐female ratio was 2.58:1, and the mandible‐to‐maxilla ratio was 1.80:1. Mean age of patients was 45.3 years. Thirty‐seven cases of recurrence and 27 cases of metastasis were recorded. Conclusion AC is a rare neoplasm of the odontogenic epithelium. A systematic review indicates that diagnoses at the early phase and a close periodic assessment for recurrence and metastasis are necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Kaplan-Meier analysis, a treatment approach of the reviewed cases, showed that treatment does not play a role in survival. But Saluja et al 19 found that the most beneficial treatment mode is surgical resection with or without radiotherapy or chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Ameloblastic carcinoma: Clinicopathological analysis of 18 cases and a systematic review

Deng

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

show abstract

“…The most favorable treatment for AC is believed to be early surgical management with or without RT or chemotherapy, determined by the site and extent of the tumor, 1 because it produces the longest mean survival time (140 months; 95% confidence interval [CI], 106-174) compared with RT (17.5 months; 95% CI, 2.95-32.1) and chemotherapy (8 months; 95% CI, 8-8). 1 The main role for RT is adjuvant or salvage treatment after surgery, 2 and patients treated with postoperative conventional RT often have long-term local control for more than 10 years with relative few late sequelae. 12 However, outcomes of nonconventional RT for each of 2 cases with recurrences or residual tumors after surgery have been reported as case presentations (Table 1).…”

Section: Discussionmentioning

confidence: 99%

“…Ameloblastic carcinoma (AC) is a rare malignant odontogenic tumor, with fewer than 200 reported cases. 1 AC combines the histologic features of ameloblastoma with those of cytologic atypia regardless of whether it has metastasized. The standard treatment for the disease is wide local excision with cervical lymph node dissection, but the efficacy of radiotherapy (RT) or chemotherapy seems limited.…”

mentioning

confidence: 99%

Proton Beam Therapy for Ameloblastic Carcinoma of the Maxilla: Report of a Rare Case

Yamagata

Ishikawa

Saito

et al. 2019

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Ameloblastic carcinoma (AC) is a rare malignant odontogenic tumor that combines the histologic features of ameloblastoma with those of cytologic atypia. The standard treatment for this lesion is wide local excision. Proton beam therapy (PBT) can deliver high irradiation doses to the target and avoid irradiation to surrounding normal tissues, but no reports of PBT for AC have been published thus far. This report describes the case of a 70-year-old woman with a pathologic diagnosis of maxillary AC who refused surgical resection and received hypofractionated PBT at a total dose of 69 Gy in 23 fractions. She has been alive for more than 5 years after PBT without any evidence of recurrence and side effects. This is the first reported case of successful treatment after curative radiation therapy for maxillary AC.

show abstract

“…Perineural invasion is an included element, although it must be emphasized that in sclerosing odontogenic carcinoma, despite extensive perineural spread, this carcinoma nevertheless carries a relatively good prognosis. 9,10,11 Margin status after surgical excision is thought to be the key prognostic feature 15,[24][25][26][27] and the best evidence relates to ameloblastic carcinoma, 2,28 primary intraosseous carcinoma, 5,17 and clear cell carcinoma. 24 Surgical margin clearances may be very small or inadequate and extension into soft tissues beyond the periosteum is usually associated with a significant risk of local recurrence.…”

Section: Discussionmentioning

confidence: 99%

Data Set for the Reporting of Malignant Odontogenic Tumors: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting

Slootweg

Odell

Baumhoer

et al. 2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

A data set has been developed for the reporting of excisional biopsies and resection specimens for malignant odontogenic tumors by members of an expert panel working on behalf of the International Collaboration on Cancer Reporting, an international organization established to unify and standardize reporting of cancers. Odontogenic tumors are rare, which limits evidence-based support for designing a scientifically sound data set for reporting them. Thus, the selection of reportable elements within the data set and considering them as either core or noncore is principally based on evidence from malignancies affecting other organ systems, limited case series, expert opinions, and/or anecdotal reports. Nevertheless, this data set serves as the initial step toward standardized reporting on malignant odontogenic tumors that should evolve over time as more evidence becomes available and functions as a prompt for further research to provide such evidence.

show abstract

Reconnoitre ameloblastic carcinoma: A prognostic update

Cited by 18 publications

References 74 publications

Ameloblastic carcinoma: Clinicopathological analysis of 18 cases and a systematic review

Ameloblastic carcinoma: Clinicopathological analysis of 18 cases and a systematic review

Proton Beam Therapy for Ameloblastic Carcinoma of the Maxilla: Report of a Rare Case

Data Set for the Reporting of Malignant Odontogenic Tumors: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting

Contact Info

Product

Resources

About